Procedure Illustrations

FL02W Procedure Illustrations Click to view

Executive Team

Related Links:

For additional information about ROX Medical, please refer to the following link:

The CONTROL-HTN Trial is registered at

Rodney Brenneman, CEO and President

Mr. Brenneman has 24 years experience in the medical device industry. He co-founded ROX Medical in 2004. Prior to ROX Medical Mr. Brenneman worked for USGI Medical as Vice President of R&D. At USGI he led a team of nine engineers and technicians to develop devices for endo-luminal GI surgery. Mr. Brenneman co-founded TheraCardia in 1998 and served as VP of R&D and Operations until 2003. Prior to 1998, Mr. Brenneman worked for Vesica Medical, acquired by Boston Scientific, Corp in 1996 and Advanced Surgical Intervention acquired by Boston Scientific, Corp in 1993. Mr. Brenneman has also done considerable consulting for very early stage medical device companies in a wide variety of specialties including Cardiology, Orthopedics, Urology, Opthamology, Neurology and Interventional Radiology.

Paul Sobotka, MD, Chief Scientific Officer

Dr. Sobotka serves as Chief Scientific Officer of ROX Medical. He has had an extensive career in clinical research and academia, as well as a prolific research and publication history of over 100 peer reviewed research articles, book chapters, and invited lectures.

Dr. Sobotka served as Chief Medical Officer of CHF Solutions Inc. since June 2004. He was responsible for the medical affairs, including clinical trials, the direction of product development, and CHF Solutions medical advisory board. He founded and served as President of Sobotka and Co., Medical Informatics and Quality Consultation. He served as Vice President, Medical Affairs of St. Mary Mercy Hospital in Michigan and Senior Director of Medical and Scientific Affairs of Merck Pharmaceutical. He served as Vice-Chairman of Medicine at Detroit Medical Center/Wayne State University, and Executive Medical Director at Merck pharmaceutical company.

Dr. Sobotka completed his Internship and Residency at the University of Michigan, Ann Arbor, and received postgraduate training in internal medicine and cardiovascular diseases at the Northwestern University, Chicago. He received his bachelor's degree from Stanford University and his Medical degree from the University of Illinois College of Medicine. He has complemented this with Healthcare Administration training at the University of Pennsylvania and Harvard School of Public Health.

Peter Balmforth, Director of Therapy Development, Education, and Sales

Mr. Balmforth has over 10 years in the medical device industry in European sales and managerial positions. Mr. Balmforth joined ROX Medical in 2010. Prior to ROX, Mr. Balmforth was Country Manager for both Atritech and Ablation Froniters, both exited in successful mergers with BSX and Medtronic, respectively. Prior, Mr. Balmforth served as Territory Manager for Endocardial Soluitons, Inc., and post aqusition by St. Jude Medical, he continued his service as Product Manager.

Chris Yelley, Director of Operations

Mr. Yelley has over 25 years experience in the medical device industry in various leadership positions. Chris joined ROX Medical in 2008. Prior to that, Chris was with ev3 Neurovascular where he led the Process development team. From 2000 through 2005 Chris was Vice President of Operations with IntraLuminal Therapeutics in Carlsbad. Prior to that Chris was Vice President of Operations with Intravascular Research Limited based in London for three years. Chris began his career with 13 years at Advanced Cardiovascular Systems (Guidant) in a variety of positions including Quality, Engineering and Manufacturing. Mr. Yelley is an experienced operations professional with expertise in developing lean and efficient manufacturing operations.